Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135903 | 0.88 | PTGDR2 (0.46) | L3MBTL1 | |
| SCHEMBL137139 | 0.83 | PPID (0.40) | NLRP3MAPTSMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL137327 | 0.82 | GAA (0.46) | MAPT | |
| SCHEMBL16501894 | 0.82 | KDM1A (0.38) | NLRP3MAPTSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL16501977 | 0.81 | PDCD1LG2 (0.36) | MAPTMEN1KMT2ATDP1 | |
| SCHEMBL136787 | 0.81 | PDK2 (0.38) | MAPTALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL134609 | 0.81 | PTGDR2 (0.47) | L3MBTL1 | |
| SCHEMBL12900596 | 0.80 | SRC (0.42) | NLRP3MAPTSMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL136363 | 0.79 | ABL1 (0.43) | L3MBTL1LMNA | |
| SCHEMBL137672 | 0.79 | MAPT (0.41) | NLRP3MAPTSMN1; SMN2ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9572785-B2 | DP2 antagonist and uses thereof | BRICKELL BIOTECH, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160136119-A1 | DP2 ANTAGONIST AND USES THEREOF | BRICKELL BIOTECH, INC. | 2016-05-19 | — | — | US | disclosed |
| US-8815917-B2 | DP2 antagonist and uses thereof | PANMIRA PHARMACEUTICALS, LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-20110034558-A1 | DP2 Antagonist and Uses Thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034558-A1 | DP2 Antagonist and Uses Thereof | PTGER2, PTGES2, PTGDR2 | NLRP3 1845/4885MAPT 4646/4885SMN1; SMN2 1223/4885 |
| US-20160136119-A1 | DP2 ANTAGONIST AND USES THEREOF | PTGER2, PTGES2, PTGDR2 | NLRP3 1845/4885MAPT 4646/4885SMN1; SMN2 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.